Cargando…

Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital

INTRODUCTION: The Japanese government’s current policy is to encourage hospitals to discharge hospital patients with schizophrenia earlier and provide them with community care. This study aims to analyze clinical and economic outcomes of different discharge strategies in psychiatric hospitals in Jap...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Yusuke, Shibata, Isao, Mahlich, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858920/
https://www.ncbi.nlm.nih.gov/pubmed/31401796
http://dx.doi.org/10.1007/s40120-019-0147-y
_version_ 1783471051191091200
author Nakamura, Yusuke
Shibata, Isao
Mahlich, Jörg
author_facet Nakamura, Yusuke
Shibata, Isao
Mahlich, Jörg
author_sort Nakamura, Yusuke
collection PubMed
description INTRODUCTION: The Japanese government’s current policy is to encourage hospitals to discharge hospital patients with schizophrenia earlier and provide them with community care. This study aims to analyze clinical and economic outcomes of different discharge strategies in psychiatric hospitals in Japan. METHODS: A simulation was conducted to compare patient relapse and hospital revenues for different discharge plans. We constructed a decision tree where each tree consists of a different Markov chain that models hospital revenue for four different discharge plans: discharge of the patient after 1, 2, or 3 months, or 4 months or more. The simulation also included variations in the medical treatment regimen in an outpatient setting as part of the discharge strategy. In particular, we looked at the choice between risperidone long-acting injectable (RLAI) and generic risperidone (RIS GE). RESULTS: The use of RLAI in an outpatient setting reduced the number of rehospitalizations compared to generic risperidone use under all discharge plans. Different discharge plans were associated with differences in economic outcomes as well. One of the key revenue drivers for the hospital was the continuation of treatment in the outpatient setting after discharge. CONCLUSION: The use of RLAI in an outpatient setting could help to prevent rehospitalization, thereby contributing to better community care. FUNDING: The Rapid Service Fee was funded by Janssen KK.
format Online
Article
Text
id pubmed-6858920
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-68589202019-12-03 Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital Nakamura, Yusuke Shibata, Isao Mahlich, Jörg Neurol Ther Original Research INTRODUCTION: The Japanese government’s current policy is to encourage hospitals to discharge hospital patients with schizophrenia earlier and provide them with community care. This study aims to analyze clinical and economic outcomes of different discharge strategies in psychiatric hospitals in Japan. METHODS: A simulation was conducted to compare patient relapse and hospital revenues for different discharge plans. We constructed a decision tree where each tree consists of a different Markov chain that models hospital revenue for four different discharge plans: discharge of the patient after 1, 2, or 3 months, or 4 months or more. The simulation also included variations in the medical treatment regimen in an outpatient setting as part of the discharge strategy. In particular, we looked at the choice between risperidone long-acting injectable (RLAI) and generic risperidone (RIS GE). RESULTS: The use of RLAI in an outpatient setting reduced the number of rehospitalizations compared to generic risperidone use under all discharge plans. Different discharge plans were associated with differences in economic outcomes as well. One of the key revenue drivers for the hospital was the continuation of treatment in the outpatient setting after discharge. CONCLUSION: The use of RLAI in an outpatient setting could help to prevent rehospitalization, thereby contributing to better community care. FUNDING: The Rapid Service Fee was funded by Janssen KK. Springer Healthcare 2019-08-10 /pmc/articles/PMC6858920/ /pubmed/31401796 http://dx.doi.org/10.1007/s40120-019-0147-y Text en © The Author(s) 2019 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Nakamura, Yusuke
Shibata, Isao
Mahlich, Jörg
Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
title Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
title_full Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
title_fullStr Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
title_full_unstemmed Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
title_short Modeling the Choice Between Risperidone Long-Acting Injectable and Generic Risperidone from the Perspective of a Japanese Hospital
title_sort modeling the choice between risperidone long-acting injectable and generic risperidone from the perspective of a japanese hospital
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858920/
https://www.ncbi.nlm.nih.gov/pubmed/31401796
http://dx.doi.org/10.1007/s40120-019-0147-y
work_keys_str_mv AT nakamurayusuke modelingthechoicebetweenrisperidonelongactinginjectableandgenericrisperidonefromtheperspectiveofajapanesehospital
AT shibataisao modelingthechoicebetweenrisperidonelongactinginjectableandgenericrisperidonefromtheperspectiveofajapanesehospital
AT mahlichjorg modelingthechoicebetweenrisperidonelongactinginjectableandgenericrisperidonefromtheperspectiveofajapanesehospital